Alnylam TTR Franchise Surges 59%, Supernus Posts Record $226.8M Revenue, BridgeBio's Attruby Up 134% in Q3 Pharma Earnings

The Quick Take

• Alnylam Pharmaceuticals' TTR franchise revenue surged 59% on strong AMVUTTRA demand, with total product revenue growing 52% in Q3 2026.
• Supernus Pharmaceuticals posted record Q3 2026 revenue of $226.8 million, raised full-year guidance, and confirmed its merger with Indivior set to close November 2.
• BridgeBio Pharma's Attruby generated 134% year-over-year revenue growth contributing to $353.2 million in Q3 revenue, narrowing operating loss to $11.6 million.
• Phathom Pharmaceuticals reaffirmed full-year 2026 guidance of $310-$325 million while expanding patient access through its Access First initiative.
• Ligand Pharmaceuticals raised adjusted EPS guidance as royalty revenue grew 51% and the transformative $730 million Zoma acquisition expanded its portfolio.

The Q3 2026 earnings season is producing exceptional results across multiple biotech and specialty pharma companies, with Alnylam, Supernus, BridgeBio, and Ligand all reporting strong momentum in their respective therapeutic franchises. Alnylam's RNA interference platform continues to demonstrate commercial potential, with the TTR franchise — targeting a rare but debilitating heart and nerve condition — growing its patient base rapidly as physician awareness and reimbursement certainty improve. The 59% TTR franchise growth validates the substantial investment in medical education and patient identification programmes that Alnylam has made over the past three years, proving that rare disease commercial models can scale meaningfully once reimbursement infrastructure is in place.

The convergence of strong commercial execution and pipeline progress across this cohort of companies represents the best possible environment for specialty pharma investors. Supernus's record revenue and imminent transformative merger with Indivior creates a larger, more diversified neuropsychiatry and addiction medicine platform with commercial synergies and combined pipeline optionality. BridgeBio's narrowing operating loss despite still carrying significant R&D expenses signals that Attruby's commercial ramp is on track to generate the cash flows needed to self-fund the company's next wave of pipeline investments in cardiovascular and rare genetic diseases, reducing dilution risk for existing shareholders.

The 340B programme uncertainty flagged by Alnylam management represents the primary risk worth monitoring across this reporting group. The 340B drug discount programme, which requires pharmaceutical companies to sell products at steep discounts to federally qualified health centres, is a significant revenue headwind for commercially successful specialty drugs, and ongoing litigation and potential legislative changes add uncertainty to the programme's scope. For investors focused on the broader biotech sector, the consistent execution across this earnings season reinforces confidence that the sector's commercial models are working effectively despite macroeconomic headwinds affecting other parts of the equity market.

Synthesized from 6 sources.